Interactions of Homocysteine, Nitric Oxide, Folate and Radicals in the Progressively Damaged Endothelium

Abstract The endothelium exerts fundamental control over vascular tone, and injury to the endothelium followed by dysfunction is an early key event preceding manifestation of vessel pathology. Both elevated plasma homocysteine and low folate status have been identified as major and independent risk factors for atherosclerosis and have stirred an enormous and still increasing interest. The damaging effects of hyperhomocysteinemia on endothelial function are, at least in part, reversible through folate supplementation. Because of the inverse relationship between plasma folate and homocysteine levels, however, it is difficult to discriminate between their respective effects. Endothelial dysfunction refers mainly to reduced bioavailability of nitric oxide (NO), which is involved in homocysteinemediated vascular damage. Accumulating evidence further suggests that radical oxygen species are fundamentally involved in hyperhomocysteinemia. NO production is determined by cofactors such as tetrahydrobiopterin, which is oxidized and depleted in conditions of oxidant stress by peroxynitrite. Deficiency of tetrahydrofolate contributes to uncoupling, turning the NO synthase into a superoxide radical-producing enzyme. It appears that progression of vascular disease is likely to determine the multiple interactions between homocysteine, NO, oxygen radicals and folate. Folate has only recently been found to exert direct anti-oxidative effects and contribute to restoration of impaired NO metabolism. Understanding of the complex interactions between homocysteine, radicals, NO and folate offers promising perspectives in the individual treatment of vascular disease. Thus, preventive and therapeutic strategies may require a more distinct approach and better discrimination of target groups for greatest possible efficacy.

[1]  M Yokoyama,et al.  Taurine Prevents the Decrease in Expression and Secretion of Extracellular Superoxide Dismutase Induced by Homocysteine: Amelioration of Homocysteine-Induced Endoplasmic Reticulum Stress by Taurine , 2001, Circulation.

[2]  N. Fink,et al.  Dietary supplement with vitamin C prevents nitrate tolerance. , 1998, The Journal of clinical investigation.

[3]  H. Knapp,et al.  Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. , 2001, Clinical science.

[4]  O. Stanger Physiology of folic acid in health and disease. , 2002, Current drug metabolism.

[5]  J. Kooner,et al.  Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[6]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[7]  L. Viinikka,et al.  Nitric oxide as a challenge for the clinical chemistry laboratory. , 1996, Scandinavian journal of clinical and laboratory investigation.

[8]  Yuan-Yuan Shi,et al.  Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. , 2001, The Journal of clinical investigation.

[9]  J. Finkelstein,et al.  Methionine metabolism in mammals. , 1990, The Journal of nutritional biochemistry.

[10]  E. Werner,et al.  l-Ascorbic Acid Potentiates Endothelial Nitric Oxide Synthesis via a Chemical Stabilization of Tetrahydrobiopterin* , 2001, The Journal of Biological Chemistry.

[11]  S. Verma,et al.  Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction , 2003, Molecular and Cellular Biochemistry.

[12]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[13]  J. Loscalzo Folate and nitrate-induced endothelial dysfunction: a simple treatment for a complex pathobiology. , 2001, Circulation.

[14]  A. Castaigne,et al.  Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. , 1992, The American journal of cardiology.

[15]  S. Moncada,et al.  Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis , 1992, Journal of cardiovascular pharmacology.

[16]  J. Zweier,et al.  Superoxide Generation from Endothelial Nitric-oxide Synthase , 1998, The Journal of Biological Chemistry.

[17]  T. Wascher,et al.  Effects of Folate Treatment and Homocysteine Lowering on Resistance Vessel Reactivity in Atherosclerotic Subjects , 2002, Journal of Pharmacology and Experimental Therapeutics.

[18]  D. Stuehr Structure-function aspects in the nitric oxide synthases. , 1997, Annual review of pharmacology and toxicology.

[19]  T. Rabelink,et al.  Folic acid reverts dysfunction of endothelial nitric oxide synthase. , 2000, Circulation research.

[20]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[21]  B. Mayer,et al.  Thiols and neuronal nitric oxide synthase: complex formation, competitive inhibition, and enzyme stabilization. , 1997, Biochemistry.

[22]  Z. Ungvari,et al.  Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: morphological and functional evidence for increased peroxynitrite formation. , 2002, The American journal of pathology.

[23]  T. Oury,et al.  Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[24]  V. Hinsbergh NO or H(2)O(2) for endothelium-dependent vasorelaxation: Tetrahydrobiopterin makes the difference. , 2001 .

[25]  Z. Ungvari,et al.  Xanthine Oxidase‐Derived Reactive Oxygen Species Convert Flow‐Induced Arteriolar Dilation to Constriction in Hyperhomocysteinemia Possible Role of Peroxynitrite , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[26]  D. Remick,et al.  Homocysteine Mediated Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human Monocytes , 2003, Circulation research.

[27]  R K Gordon,et al.  S‐Adenosylmetliionine and methylation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  T. Rabelink,et al.  Influence of folic acid on postprandial endothelial dysfunction. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[30]  M Yamamoto,et al.  Effects of homocysteine on the binding of extracellular‐superoxide dismutase to the endothelial cell surface , 2000, FEBS letters.

[31]  H. Knapp,et al.  Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. , 1999, Circulation.

[32]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[33]  HidemiNonaka,et al.  Taurine Prevents the Decrease in Expression and Secretion of Extracellular Superoxide Dismutase Induced by Homocysteine , 2001 .

[34]  Y. Hattori,et al.  HMG-CoA Reductase Inhibitor Increases GTP Cyclohydrolase I mRNA and Tetrahydrobiopterin in Vascular Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[35]  M. Nakamura,et al.  The cardiovascular effects and implications of peroxynitrite. , 1999, Cardiovascular research.

[36]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[37]  T. Gori,et al.  Folic Acid Prevents Nitroglycerin-Induced Nitric Oxide Synthase Dysfunction and Nitrate Tolerance: A Human In Vivo Study , 2001, Circulation.

[38]  S. Verma,et al.  Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. , 2002, American journal of physiology. Heart and circulatory physiology.

[39]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[40]  V. Hinsbergh NO or H2O2 for Endothelium-Dependent Vasorelaxation , 2001 .

[41]  Jonathan Goodfellow,et al.  Folic Acid Improves Endothelial Function in Coronary Artery Disease via Mechanisms Largely Independent of Homocysteine Lowering , 2002, Circulation.

[42]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[43]  E. Werner,et al.  In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[44]  W. Koppenol,et al.  The basic chemistry of nitrogen monoxide and peroxynitrite. , 1998, Free radical biology & medicine.

[45]  D. Kennedy,et al.  Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs. , 1997, Atherosclerosis.

[46]  Y. T. Lee,et al.  Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. , 2000, Circulation.

[47]  J. Genest,et al.  Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. , 2000, Journal of the American College of Cardiology.

[48]  C. Maxwell,et al.  Serum Folate Levels and Subsequent Adverse Cerebrovascular Outcomes in Elderly Persons , 2002, Dementia and Geriatric Cognitive Disorders.

[49]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[50]  T. Lincoln,et al.  Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. , 1997, The Journal of clinical investigation.

[51]  B. Gaston,et al.  Nitric oxide and thiol groups. , 1999, Biochimica et biophysica acta.

[52]  K. Hirata,et al.  Superoxide Generation in Directional Coronary Atherectomy Specimens of Patients With Angina Pectoris: Important Role of NAD(P)H Oxidase , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[53]  D. Glogar,et al.  Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. , 1997, Atherosclerosis.

[54]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[55]  P. Durand,et al.  Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. , 1996, Atherosclerosis.

[56]  K. Pritchard,et al.  Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Newcombe,et al.  Oral folate enhances endothelial function in hyperhomocysteinaemic subjects , 1999, European journal of clinical investigation.

[58]  J. Ahlner,et al.  Organic nitrate esters: clinical use and mechanisms of actions. , 1991, Pharmacological reviews.

[59]  G. Heusch,et al.  Plasma Nitrosothiols Contribute to the Systemic Vasodilator Effects of Intravenously Applied NO: Experimental and Clinical Study on the Fate of NO in Human Blood , 2002, Circulation research.

[60]  R. Brooks,et al.  NO-Dependent Vasorelaxation Is Impaired After Gene Transfer of Inducible NO-Synthase , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[61]  I. Mcdowell,et al.  Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? , 2002, Atherosclerosis.

[62]  Gabor Kaley,et al.  Increased Superoxide Production in Coronary Arteries in Hyperhomocysteinemia: Role of Tumor Necrosis Factor-&agr;, NAD(P)H Oxidase, and Inducible Nitric Oxide Synthase , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[63]  G. D. De Keulenaer,et al.  Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. , 1998, The Biochemical journal.

[64]  E. Werner,et al.  Tetrahydrobiopterin, Cytokines, and Nitric Oxide Synthesis 1 , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[65]  T. Hagve,et al.  Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. , 2001, The American journal of medicine.

[66]  A. M. Lefer,et al.  Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion , 1991, Critical care medicine.

[67]  J. Loscalzo,et al.  Homocyst(e)ine Decreases Bioavailable Nitric Oxide by a Mechanism Involving Glutathione Peroxidase* , 1997, The Journal of Biological Chemistry.

[68]  A. M. Lefer,et al.  Direct measurement of nitric oxide release from vascular endothelial cells. , 1996, Journal of applied physiology.

[69]  G. Hedenstierna,et al.  Inhaled Nitric Oxide Selectively Reverses Human Hypoxic Pulmonary Vasoconstriction without Causing Systemic Vasodilation , 1993, Anesthesiology.

[70]  B. Mayer,et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. , 2000, Circulation research.

[71]  P. Aukrust,et al.  Folic Acid Treatment Reduces Chemokine Release From Peripheral Blood Mononuclear Cells in Hyperhomocysteinemic Subjects , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[72]  D. Harrison,et al.  New insights into mechanisms underlying nitrate tolerance. , 1996, The American journal of cardiology.

[73]  B. Mayer,et al.  Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.

[74]  P. Tsao,et al.  Homocysteine Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine , 2001, Circulation.

[75]  Y. Kiuchi,et al.  Presence of excess tetrahydrobiopterin during nitric oxide production from inducible nitric oxide synthase in LPS-treated rat aorta. , 1999, Life sciences.

[76]  J. Stamler,et al.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. , 1993, The Journal of clinical investigation.

[77]  P. Aukrust,et al.  Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects , 2003, British Journal of Nutrition.

[78]  H. Morrison,et al.  Serum Folate and Risk of Fatal Coronary Heart Disease , 1996 .

[79]  D. Harrison,et al.  Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.

[80]  J. Loscalzo,et al.  Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. , 2000, The Journal of clinical investigation.

[81]  S. Henning,et al.  Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. , 1997, Free Radical Biology & Medicine.

[82]  E. Werner,et al.  Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. , 1996, Biochemistry.

[83]  J. Loscalzo The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[84]  S. Moncada,et al.  Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor , 1986, Nature.

[85]  P. Pagliaro Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[86]  K. Woo,et al.  Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. , 1999, Journal of the American College of Cardiology.

[87]  Z. Katusic Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? , 2001, American journal of physiology. Heart and circulatory physiology.

[88]  A. M. Lefer,et al.  Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. , 1999, General pharmacology.

[89]  W. Renner,et al.  Vascular Dysfunction in Hyperhomocyst(e)inemia. Implications for Atherothrombotic Disease , 2001, Clinical chemistry and laboratory medicine.

[90]  S. Tyagi,et al.  Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. , 2002, American journal of physiology. Cell physiology.

[91]  J. Higgins,et al.  Folate protects against oxidative modification of human LDL , 2001, British Journal of Nutrition.

[92]  J. Zweier,et al.  Inducible Nitric-oxide Synthase Generates Superoxide from the Reductase Domain* , 1998, The Journal of Biological Chemistry.

[93]  M. Goligorsky,et al.  Effects of homocysteine on endothelial nitric oxide production. , 2000, American journal of physiology. Renal physiology.

[94]  C. Nathan,et al.  Inducible nitric oxide synthase: identification of amino acid residues essential for dimerization and binding of tetrahydrobiopterin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[95]  S. Clarke,et al.  RNA and protein interactions modulated by protein arginine methylation. , 1998, Progress in nucleic acid research and molecular biology.

[96]  P. Vanhoutte,et al.  The endothelium as a regulator of vascular smooth muscle proliferation , 1993 .

[97]  A. M. Lefer,et al.  Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[98]  G. Wang,et al.  Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. , 2000, The Biochemical journal.

[99]  P. Ueland,et al.  Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. , 1989, The Journal of laboratory and clinical medicine.

[100]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[101]  H P Misra,et al.  Generation of superoxide free radical during the autoxidation of thiols. , 1974, The Journal of biological chemistry.

[102]  R. Newcombe,et al.  Folate Improves Endothelial Function in Coronary Artery Disease: An Effect Mediated by Reduction of Intracellular Superoxide? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[103]  M. Lewis,et al.  The nature of endothelium-derived vascular relaxant factor , 1984, Nature.

[104]  A. Hausladen,et al.  Oxidative modifications in nitrosative stress , 1998, Nature Structural Biology.

[105]  T. Lakka,et al.  Low Dietary Folate Intake Is Associated With an Excess Incidence of Acute Coronary Events: The Kuopio Ischemic Heart Disease Risk Factor Study , 2001, Circulation.

[106]  S. Tyagi,et al.  Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. , 2002, American journal of physiology. Cell physiology.

[107]  G. Starkebaum,et al.  Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. , 1986, The Journal of clinical investigation.

[108]  T. Podor,et al.  Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. , 1999, Blood.

[109]  S. Vollset,et al.  Homocysteine and cardiovascular disease. , 1998, Annual review of medicine.

[110]  P. Kubes,et al.  Nitric oxide modulates microvascular permeability. , 1992, The American journal of physiology.

[111]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[112]  D. Bunout,et al.  Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. , 2000, Nutrition.

[113]  J. Abe,et al.  Reactive oxygen species as mediators of signal transduction in cardiovascular disease. , 1998, Trends in cardiovascular medicine.

[114]  J. Kooner,et al.  Improved Vascular Endothelial Function After Oral B Vitamins: An Effect Mediated Through Reduced Concentrations of Free Plasma Homocysteine , 2000, Circulation.

[115]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[116]  T. Imaizumi,et al.  Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. , 1999, Clinical science.

[117]  P. Tsao,et al.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.

[118]  J. Kooner,et al.  Hyperhomocysteinemia : An Effect Reversible With Vitamin C Therapy Demonstration of Rapid Onset Vascular Endothelial Dysfunction After , 1999 .

[119]  O. Vintermyr,et al.  Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of non‐transformed, transformed, proliferating, and quiescent cells in culture , 1991, Journal of cellular physiology.

[120]  M. Lewis,et al.  Endothelium Derived Relaxant Factor , 1985, Journal of the Royal College of Physicians of London.

[121]  M. Creager,et al.  Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. , 1997, Circulation.

[122]  E. Werner,et al.  Tetrahydrobiopterin binding to macrophage inducible nitric oxide synthase: heme spin shift and dimer stabilization by the potent pterin antagonist 4-amino-tetrahydrobiopterin. , 1997, Biochemistry.

[123]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[124]  S. Rajagopalan,et al.  Altered Tetrahydrobiopterin Metabolism in Atherosclerosis: Implications for Use of Oxidized Tetrahydrobiopterin Analogues and Thiol Antioxidants , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[125]  H. Blom,et al.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.

[126]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[127]  M. S. Katz,et al.  EGF inhibits muscarinic receptor-mediated calcium signaling in a human salivary cell line. , 2000, American journal of physiology. Cell physiology.

[128]  A. M. Lefer,et al.  Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. , 1996, Circulation research.

[129]  J. Kastelein,et al.  5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. , 1998, Circulation.

[130]  K. Woo,et al.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 1997, Circulation.

[131]  B. Mayer,et al.  A synthetic peptide corresponding to the putative dihydrofolate reductase domain of nitric oxide synthase inhibits uncoupled NADPH oxidation. , 1997, Nitric oxide : biology and chemistry.

[132]  S. Hernández-Díaz,et al.  Dietary Folate and the Risk of Nonfatal Myocardial Infarction , 2002, Epidemiology.